Loading data for INDV — first visit, this takes a few seconds.
Indivior Pharmaceuticals, Inc.
35.69 +1.34 (3.90%)
- Market Cap
- $4.21B
- Volume
- 1.68M
- Dividend yield
- n/a
- Next earnings date
- Nov 5, 2026
Indivior Pharmaceuticals, Inc. (INDV) Stock Price, Analysis & Data
Intrinsic Value
Analyst Forecast
Stock Forecasts →Latest Earnings
| Reported | Vs estimate | YoY Change | |
|---|---|---|---|
| Revenue | $343.0M | n/a | +13.58% |
| EPS | $1.15 | +$0.23 | +125.49% |
Metrics
- Bid
- 25.44
- Market Cap
- 4.21B
- Revenue (ttm)
- 1.33B
- Net Income (ttm)
- 356M
- 1.11
- 2.9
- 12.31
- 7.31
- P/B (ttm)
- -20.24
- P/S (ttm)
- 3.16
- Earnings Date
- Nov 5, 2026
- Ask
- 44.48
- Volume
- 1,680,787
- Avg. Volume (20D)
- 2,109,700
- Open
- 34.76
- Previous Close
- 34.35
- Day's Range
- 34.47 - 35.90
- 52-Week Range
- 22.22 - 42.81
- Analyst
- n/a
- Price Target
- n/a
- Dividends
- n/a
- Ex-Dividend Date
- Jun 16, 2016
About Indivior Pharmaceuticals, Inc.
View profile →Indivior Pharmaceuticals, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. It develops medicines to treat substance use disorders. The company's core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; and SUBOXONE Film, a buprenorphine and naloxone sublingual film. It also manufactures SUBOXONE Tablet, a buprenorphine and naloxone sublingual tablet; and SUBUTEX Tablet, a buprenorphine sublingual tablet for the treatment of opioid use disorder (OUD). In addition, the company is developing INDV-2000, a selective orexin-1 receptor antagonist that is in Phase 2 clinical trial for the treatment of moderate to severe OUD; and INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc. The company was formerly known as Indivior PLC. and changed its name to Indivior Pharmaceuticals, Inc. in January 2026. Indivior Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.
Indivior Pharmaceuticals, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. It develops medicines to treat substance use disorders. The company's core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; and SUBOXONE Film, a buprenorphine and naloxone sublingual film. It also manufactures SUBOXONE Tablet, a buprenorphine and naloxone sublingual tablet; and SUBUTEX Tablet, a buprenorphine sublingual tablet for the treatment of opioid use disorder (OUD). In addition, the company is developing INDV-2000, a selective orexin-1 receptor antagonist that is in Phase 2 clinical trial for the treatment of moderate to severe OUD; and INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc. The company was formerly known as Indivior PLC. and changed its name to Indivior Pharmaceuticals, Inc. in January 2026. Indivior Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.
Sector Healthcare
IPO Date Dec 29, 2014
Employees 827
Stock Exchange NasdaqGS
Ticker Symbol INDV
Website https://www.indivior.com